Novartis Access
Launched in September 2015, Novartis Access is an unprecedented new Novartis-wide initiative to drive patient access to our medicines in lower-income countries. It is the latest addition to our ongoing efforts to enhance access to affordable, high-quality healthcare for patients at every level of the income pyramid.
The Novartis Access program, which is operated by Sandoz, focuses on affordability and availability of targeted on- and off-patent medicines addressing key non-communicable diseases (NCDs) – cardiovascular disease, diabetes, respiratory illnesses and breast cancer. Its portfolio of 15 medicines, many of which are Sandoz products, is provided to governments, NGOs and other public-sector customers at a price of USD 1 per treatment per month.
How much do you know about noncommunicable diseases? How are they impacting developing nations? Test your knowledge with a short quiz.
In recent years, noncommunicable diseases (NCDs) such as cardiovascular diseases, diabetes, respiratory diseases and cancers have become an emerging pandemic globally with disproportionately higher rates in developing countries.
Novartis is deploying a mix of access models covering infectious and noncommunicable diseases. Our approaches are tailored to the different local needs.